key: cord-0826151-0l421381
authors: Wang, Chunyan; van Haperen, Rien; Gutiérrez-Álvarez, Javier; Li, Wentao; Okba, Nisreen M.A.; Albulescu, Irina; Widjaja, Ivy; van Dieren, Brenda; Fernandez-Delgado, Raul; Sola, Isabel; Hurdiss, Daniel L.; Daramola, Olalekan; Grosveld, Frank; van Kuppeveld, Frank J.M.; Haagmans, Bart L.; Enjuanes, Luis; Drabek, Dubravka; Bosch, Berend-Jan
title: Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein
date: 2020-10-20
journal: bioRxiv
DOI: 10.1101/2020.10.20.346916
sha: b96b35008ac55d0cb336af75050a8375e9c99c9e
doc_id: 826151
cord_uid: 0l421381

The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry. As such, it is an attractive target for the development of protective antibodies and vaccines. Here we describe two human monoclonal antibodies, 1.6C7 and 28D9, that display a remarkable cross-reactivity against distinct species from three Betacoronavirus subgenera, capable of binding the spike proteins of SARS-CoV and SARS-CoV-2, MERS-CoV and the endemic human coronavirus HCoV-OC43. Both antibodies, derived from immunized transgenic mice carrying a human immunoglobulin repertoire, blocked MERS-CoV infection in cells, whereas 28D9 also showed weak cross-neutralizing potential against HCoV-OC43, SARS-CoV and SARS-CoV-2 in a neutralization-sensitive virus pseudotyping system, but not against authentic virus. Both cross-reactive monoclonal antibodies were found to target the stem helix in the spike protein S2 fusion subunit which, in the prefusion conformation of trimeric spike, forms a surface exposed membrane-proximal helical bundle, that is antibody-accessible. We demonstrate that administration of these antibodies in mice protects from a lethal MERS-CoV challenge in both prophylactic and/or therapeutic models. Collectively, these antibodies delineate a conserved, immunogenic and vulnerabe site on the spike protein which spurs the development of broad-range diagnostic, preventive and therapeutic measures against coronaviruses.

While these viruses are typically associated with mild respiratory illnesses (common 61 colds) 5-7 , they can cause significant morbitity, and even mortality, in 62 immunocompromised individuals 8 . All these viruses made their way into humans from 63 an animal reservoir, illustrating the zoonotic threat posed by coronaviruses and their 64 pandemic potential 1, [9] [10] [11] . The devastating socio-economic consequences of the 65 COVID-19 pandemic urges the development of intervention strategies that can mitigate 66 outbreak of future emerging coronaviruses.

cell-cell fusion but does not impede MERS-Secto/DPP4 receptor interaction (Fig. 2c  177 and d), suggesting that both S2-targeting antibodies prevent the membrane fusion 178 function of the spike S2 subunit that is required for infection. 179 180 mAbs 1.6C7 and 28D9 target a linear epitope located in the stem region of the S2 181 fusion subunit 182

Both antibodies were tested for competitive binding to MERS-Secto using biolayer 183 interferometry. MERS-Secto binding by 1.6C7 antibody compelety prevented binding of 184 28D9, and vice versa, suggesting that the antibodies target overlapping epitopes (Fig.  185   3a) . To assess the epitope conformational specificity, we compared the ELISA 186 reactivity of 1.6C7 and 28D9 to untreated MERS-CoV Secto antigen versus antigen that 187 was heat-denatured in the presence of SDS and DTT. Both antibodies reacted equally 188 well with non-denatured and denatured proteins, unlike a MERS-S1 targeting antibody 189 7.7G6 43 that only reacted with non-denatured antigen. These data indicate that 1.6C7 190 and 28D9 likely bind a linear, contiguous sequence of amino acids in MERS-S (Fig.  191   3b) . 192

As both antibodies may bind a linear epitope, we aimed to map their epitope 193 location by ELISA using an array of overlapping synthetic peptides (30-mer peptides 194

with an overlap of 15 residues) covering the conserved C-terminal part of the S2ecto (residues 869-1,288). Both antibodies appeared to bind a 15-residue-long region 196 (MERS-S residues 1,229-1,243) positioned just upstream of the heptad repeat 2 (HR2) 197 region in the MERS-S2 fusion subunit (Fig. 3c) . Analysis of 1.6C7/28D9 antibody 198 binding to N-and C-terminally truncated versions of the 15-mer peptide fragment 199

To corroborate the epitope alanine scanning data, we assessed ELISA reactivity of the 211 1.6C7/28D9 antibodies to single site MERS-Secto mutants containing alanine 212 substitutions in the core epitope region. Consistent to the peptide alanine scanning, 213 alanine substitution of the three residues D 1236 , F 1238 and F 1239 abrogated MERS-Secto 214 binding by both antibodies, but not that of the anti-MERS-S1 control antibody 7.7G6 215 (Fig. 4c) . 216

To assess the individual contribution to antibody binding of identified residues in 217 the context of the membrane-anchored full-length spike protein, a flow cytometry-218 based assay was performed measuring antibody binding to cell-surface expressed 219 MERS-S mutants (Fig. 4d) . The anti-MERS-S1 7.7G6 antibody was used to control 220 cell surface expression levels of the single-site mutants. With the exception of the 221 L 1235 A mutant, all mutant spike proteins displayed surface expression levels similar to 222 wildtype. Alanine substitutions of residues in the MERS-S core epitope region 223 (D 1233 ELDEFFK 1240 ) reduced binding by both antibodies to a varying extent, although 224 analysis of binding data for the L 1235 A mutant was compromised by reduced cell 225 surface expression level. Consistent with the ELISA-based analysis (Fig. 4a and c) , 226 mutation of D 1236 , F 1238 and F 1239 most strongly affected binding by both antibodies. 227

Both antibodies showed similar binding patterns in all three antigen binding assays 228 (Fig. 4a , c-d and Suppl. Fig. 4 ), yet subtle differences in the reactivities were observed 229 that may rationalize differences between these two antibodies and their cross-spike 230 binding properties. 231

The identified residues in the spike epitope region (D 1233 ELDEFFK 1240 in MERS-232 S) contributing to 1.6C7/28D9 binding are not fully conserved in the targeted 233 betacoronavirus spike proteins, with variations found in three residues (D 1233 , D 1236 and 234 F 1238 in MERS-S) that are key to binding by both cross-reactive antibodies (Fig. 4b) . 235

To assess contribution of these amino acid variations to antibody reactivity, single site 236 substitutions were made in MERS-S. Soluble and full-length D 1233 S, D 1233 E, D 1236 S, 237 F 1238 W and F 1238 Y MERS-S mutants were tested for antibody binding by respectively 238 ELISA (Fig. 4c ) and flow cytometry (Fig. 4d) , as described above. Substitution of D 1233 239 in MERS-S to serine (S, found in HKU1-S) or glutamic acid (E, found in SARS-, 240 SARS2-, OC43-and MHV-S) still allowed efficient binding by both antibodies. In 241 addition, but contrary to the MERS-S F 1238 A mutant, the MERS-S mutants in which 242 indicate a degree of sequence variability that is allowed in the epitope region without 245 compromising antibody binding. Particularly, different aromatic residues (Phe, Trp and 246

Tyr) seem to be permitted at residue position 1238. Conversely, the D 1236 S substitution 247 in MERS-S (found in HKU1-S) fully abrogated binding by both antibodies. The 248 reciprocal S 1236 D substitution in HKU1-S was sufficient to rescue binding by 28D9, and 249 to a lesser extend by 1 .6C7 (Suppl. Fig. 5) . These data rationalize the ability of both 250 antibodies to bind spike proteins of MERS-CoV, SARS-CoV, SARS-CoV-2, HCoV-251 OC43 and MHV as well as the inability of both antibodies to bind the HCoV-HKU1 spike 252 protein. Evidently, epitope mapping of the two antibodies raised in two different animal 253 immunization experiment revealed that they target the same epitope. We identified a 254 third cross-reactive monoclonal antibody from an independent mouse immunization 255 experiment (DNA+protein immunization), that targets the same site on betacoronavirus 256 spike proteins (mAb 18H2, Suppl. Fig. 6 ), indicating that this epitope is immunogenic 257 and efficient in the induction of cross-reactive antibodies. 258

Sequence analysis of the variable regions of the 1.6C7, 28D9 and 18H2 259 antibodies identified that their heavy and light chains were derived from the IGHV6-1 260 and IGKV4-1 germline precursor, respectively. Six somatic hypermutation were found 261 in the VH region for 28D9, and five for 1.6C7. Seven somatic hypermutation were found 262 in the VL region for 28D9, and two for 1.6C7 (Suppl. Fig. 7) . 263

Glycans on antigens are frequently found to be a determinant for antibody binding. 264

We found that antigen deglycosylation resulted in lower binding of 28D9 to OC43-Secto, 265

MHV-Secto and SARS-Secto using western blotting (Supl. Fig. 8a) , in contrast to 1.6C7. 266

We tested the involvement of an N-linked glycan located one residue downstream of 267

Although the 28D9/1.6C7 epitope region was present in five betacoronavirus spike 280 protein ectodomains of which cryo-EM prefusion structures were elucidated, the C-281 terminally located epitope region was not or only poorly resolved in the cryo-EM maps, 282

indicative for conformational flexibility of the epitope region 22, 32, 44 . However, the 283 epitope was recently revealed in trimeric pre-and postfusion SARS-CoV-2 spike 284 structures that were reconstructed by cryo-EM using purified full-length spike protein 285 31 . In the prefusion SARS-CoV-2 spike, the epitope region (E 1150 ELDKYFK 1157 in 286 SARS2-S) is part of a 20-residue-long α-helix at the membrane-proximal base of the 287 molecule (Fig. 5b) . The corresponding region in HCoV-NL63 spike protein was 288 designated as 'stem' helix 44 . The stem helices of three S protomers align along the 289 three-fold symmetry axis and form a helical bundle accessible for antibody binding, 290 and which displays a relatively high level of conserved surface exposed residues 291 across betacoronavirus spike proteins (Suppl. Fig. 9 ). Remarkably, both antibodies 292 can also bind the postfusion spike structure as demonstrated by their ability to bind the 293 MHV S2ecto (Fig. 1a ) that was earlier solved in its postfusion structure 45 . In the S2 294 postfusion structure, the N-and C-terminal residues of the stem helix are uncoiled 295 whereas the middle part (F 1148 KEELD 1153 in SARS2-S) is still folded as a short, surface 296 exposed helix, which docks perpendicular to the central coiled coil 31, 45 . 297 298 Antibodies towards the stem helix epitope are elicited during natural infection 299

We next analysed whether antibodies towards the stem helix epitope or other linear 300 Suppl. Fig. 10) . These data indicate that antibodies towards this epitope are efficiently 312 elicited not only in spike-immunized mice but also during natural infection of humans 313 and dromedary camels. antibody 43 were taken along as controls (Fig. 7a) . The percentage of survival and 324 weight change was monitored daily for 10 days. In isotype control pre-and post-325 treated mice, MERS-CoV causes lethal disease with 100% lethality between 8 and 10 326 days and showed significant weight loss. In contrast, both pre-and post-treatment of 327 1.6C7 protected mice from death, and that of 7.7G6 protect 80-100% of mice from 328 death. Relative to isotype control treated mice, mice treated with either 7.7G6 or 1.6C7 329 showed reduced weight loss (Fig. 7a) . 330

To investigate the reduction in pathology and viral loads, lungs of mice were 331 harvested on day 3 (3 animals) and 8-10 (5 animals) post infection. In isotype control 332 treated mice, no obvious difference of viral RNA was observed compared to non-333 antibody treated (Mock-treated) mice. However, mice treated with 1.6C7 before or after 334 virus challenge, demonstrated 1-2 log reduction in viral RNA titers on day 3 post 335 exposure, whereas a 2-3 log reduction was seen at 8-10 dpi (Suppl. Fig. 11a) . A 336 similar reduction was seen for the isolation of infectious virus at day 3, whereas at day 337 8-10 post exposure no infectious virus could be isolated from the lungs of the 1.6C7 338 pre-and post-exposure treated mice (Suppl. Fig. 11a ). Mice treated with 1.6C7 before 339 and after infection showed greatly reduced lung pathology and inflammation following intranasal infection with a lethal dose of MERS-CoV or of SARS-CoV (Fig. 7b and c) , 346

respectively. The percentage of survival and weight change of mice was monitored 347 daily for 13 days. Whereas no protection was seen against SARS-CoV challenge, four 348 out of five animals infused with 200 µg 28D9 antibody survived MERS-CoV infection 349 and did not display significant weight loss. 350 351

We report two human monoclonal antibodies that are able to bind the spike proteins of 353 betacoronaviruses from three different subgenera. Both antibodies were found to 354 target a conserved and immunogenic epitope in membrane-proximal stem region on 355 the S2 fusion subunit, that is also recognized by the immune system during natural We showed that the stem-helix targeting antibodies effectively blocked MERS-373

CoV infection in cultured cells and provided prophylactic and therapeutic protection to 374 mice against a lethal dose MERS-CoV challenge. This epitope was hitherto not 375 described as a target of neutralizing antibodies, although monoclonal antibodies with 376 neutralizing activity were found to target the sequences flanking the stem-helix epitope, 377

including the downstream HR2 region 49-51 . Membrane fusion by the S2 subunit is 378 mediated through extensive conformational rearrangements, particularly in the epitope containing region. Elucidation of pre-and post-fusion spike structures reveals that 380 dissociation of the three epitope-containing stem-helices in the prefusion spike trimer 381 is required for formation of the highly stable postfusion structure 31, 45, 52, 53 . Though the 382 precise mechanism of neutralization by these two antibodies remains to be defined, at 383 least two mechanisms of neutralization are conceivable: the binding of antibodies may 384 destabilize the bundle of stem helices in the prefusion spike protein initiating premature 385 spike activation. Alternatively, antibody binding may obstruct six-helix bundle formation 386 of the spike protein during fusion 54 . Intriguingly, despite having different conformations 387 resulting from the structural rearrangement during fusion, the epitope in pre-and post-388 fusion spike conformation could still be bound by both antibodies, suggesting either 389 epitope recognition of the structurally conserved part of the epitope in the two spike 390 conformations, or through an 'induced fit' mechanism at the binding interface 55 . 391

Neutralization of authentic human-infecting coronaviruses, other than MERS-CoV, 392

was not observed by these two antibodies, although weak cross-neutralizing capacity 393 against pseudotyped viruses was seen for 28D9. This monoclonal antibody displayed 394 high ELISA-reactivity to the spike proteins of HCoV-OC43, SARS-CoV, SARS-CoV-2. 395

The lack of robust cross-neutralization by 28D9 may result from the approximately 5-396 to 10-fold higher equilibrium dissociation constants towards these spike proteins, 397 relative to MERS-S, inferred by subtle differences in epitope composition. Structural 398 insight into the 28D9 antibody binding mode to the stem helix epitope of targeted CoV 399 spike proteins may guide antibody affinity improvement by structure-based design to 400 increase breadth of neutralization. 401

The conserved stem helix epitope appears to be highly immunogenic. This is 402 demonstrated by the independent isolation of three cross-reactive antibodies (28D9, interferometry. Immobilized MERS-Secto antigen was saturated in binding with a given 967 mAb (step 1) and then exposed to binding by a second mAb (step 2). Additional binding 968 of the second antibody indicates the presence of an unoccupied epitope, whereas lack 969 of binding indicates epitope blocking by mAb1. As a control, the first mAb was also 970 included in the second step to check for self-competition. Competitive binding was 971 tested for the S2-targeting 1.6C7 and 28D9 antibodies and a MERS-S1 antibody 972 control (7.7G6) 43 . b. 1.6C7 and 28D9 recognize a linear epitope. ELISA binding curves 973 of 1.6C7 and 28D9 to untreated MERS-Secto (non-denatured: 'nd') versus MERS-Secto 974 that was heat-denatured in the presence of SDS and DTT (denatured: 'd'). Two 975 antibodies targeting the MERS-S1 domain (7.7G6) and the 8-residue long linear Strep- IDFQDELDEFFKNVS  ADFQDELDEFFKNVS  IAFQDELDEFFKNVS  IDAQDELDEFFKNVS  IDFADELDEFFKNVS  IDFQAELDEFFKNVS  IDFQDALDEFFKNVS  IDFQDEADEFFKNVS  IDFQDELAEFFKNVS  IDFQDELDAFFKNVS  IDFQDELDEAFKNVS  IDFQDELDEFAKNVS  IDFQDELDEFFANVS  IDFQDELDEFFKAVS  IDFQDELDEFFKNAS 

Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ Ψ D B C A

A pneumonia outbreak associated with a new coronavirus of probable 714 bat origin

Coronaviridae Study Group of the International Committee on

Severe acute respiratory syndrome

World Health Organization. MERS situation update

Epidemiology and clinical presentations of the four human coronaviruses 229E

NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method

Human coronaviruses: a review of virus-729 host interactions

Clinical impact of human coronaviruses 731 229E and OC43 infection in diverse adult populations

Human coronavirus OC43 associated with fatal encephalitis

Epidemiology, genetic recombination, and pathogenesis of 736 coronaviruses

Interspecies transmission and 738 emergence of novel viruses: lessons from bats and birds

Bat origin of human coronaviruses

Antibodies from a human survivor define sites of vulnerability for 754 broad protection against ebolaviruses

Multifunctional pan-ebolavirus antibody recognizes a site of broad 756 vulnerability on the ebolavirus glycoprotein

Cross-reactive antibodies in convalescent SARS patients' sera 758 against the emerging novel human coronavirus EMC (2012) by both 759 immunofluorescent and neutralizing antibody tests

Structures of human antibodies bound to SARS-CoV-2 spike 761 reveal common epitopes and recurrent features of antibodies

Broad neutralization of SARS-related viruses by human 763 monoclonal antibodies

Stabilized coronavirus spikes are resistant to 765 conformational changes induced by receptor recognition or proteolysis

The human coronavirus HCoV-229E S-protein structure and receptor 768 binding

Structures of MERS-CoV spike glycoprotein in complex with sialoside 770 attachment receptors

Cryo-EM structure of infectious bronchitis coronavirus spike protein 772 reveals structural and functional evolution of coronavirus spike proteins

Cryo-Electron Microscopy Structure of Porcine Deltacoronavirus

Spike Protein in the Prefusion State

Prophylactic efficacy of 28D9 against SARS-CoV infection. Five 16-1057 week old Balb-C mice were mock-infected or administered with the 50 or 200 μg of 1058 28D9 or isotype control antibody via intraperitoneal injection 24 hours before intranasal 1059 infection with a lethal dose of mouse adapted SARS-CoV